J&J, Bayer Fail to Win Expanded U.S. Backing for XareltoAnna Edney
Johnson & Johnson and Bayer AG failed to gain U.S. approval to expand the use of their blood thinner Xarelto to prevent heart attacks and strokes in patients with serious chest pain or a previous heart attack.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.